aBstract
Background and study aims A new esophageal stent with two anti-migration features was developed to minimize migration. The aim of this study was to evaluate the clinical efficacy and safety of this stent in patients with malignant dysphagia.
patients and methods A total of 40 patients with dysphagia due to a malignant obstruction of the esophagus were prospectively enrolled in this cohort study.
results Stent placement was technically successful in 39 patients (98%). The median dysphagiafree time after stent placement was 220 days (95% confidence interval 94-345 days). Nine patients (23%) experienced recurrent dysphagia due to tissue overgrowth (n = 2), stent fracture (n = 1), and partial (n = 5) or complete (n = 1) stent migration. A total of 16 serious adverse events occurred in 14 patients (36%), with hemorrhage (n = 3) and severe nausea or vomiting (n = 3) being the most common causes.
conclusions This new stent design was effective for the palliation of malignant dysphagia and had a low rate of recurrent dysphagia. However, despite the anti-migration features, stent migration was still a major cause of recurrent dysphagia. Furthermore, treatment was associated with a high adverse event rate.
introduction Dysphagia is a frequently encountered symptom in patients presenting with esophageal and gastric cardia cancer or, less frequently, obstruction due to extrinsic malignant compression. Due to the late presentation of symptoms, more than 50% of patients already have incurable disease at presentation. For these patients, palliative therapy is the only option to relieve dysphagia. 1 Of the various treatment modalities available, placement of a self-expandable metal stent (SEMS), is still the most commonly performed treatment option worldwide. 2 Many studies have shown that SEMS placement is both effective and safe for the palliation of malignant dysphagia. However, the main drawback of this treatment is the high rate of recurrent dysphagia (30%-40%), which requires repeat endoscopy. 3, 4 The main cause of recurrent dysphagia in partially covered SEMS is tissue ingrowth and overgrowth through the uncovered stent mesh (15%), [5] [6] [7] whereas in fully covered (FC) SEMS, the main cause is stent migration (14%). 5, 8 In an attempt to address the high migration rate of FCSEMS and thus reduce the recurrent dysphagia rate, we developed the fully covered Hanaro Flap stent (Esophagus Flap BSUtrecht design; M.I. Tech, Seoul, South Korea). The stent is designed to resist tissue ingrowth but also to prevent stent migration by the incorporation of two specific antimigration features -stent-anchoring flaps attached around the stent body and flared stent ends. However, whether these anti-migration features indeed reduce stent migration has yet to be proven.
The aim of this prospective follow-up study was to evaluate the clinical efficacy (with particular focus on recurrent dysphagia due to stent migration) and safety of the Hanaro Flap stent for the palliation of malignant dysphagia.
patiEnts and mEthods patients Between June 2011 and October 2012, consecutive patients undergoing stent placement for palliation of malignant dysphagia were enrolled in this prospective multicenter study. Patients were included if they had dysphagia (grade ≥2 according to Ogilvie) due to a malignant stricture, defined as a nonoperable malignant obstruction of the esophagus or esophagogastric junction, extrinsic malignant compression, or recurrent malignant dysphagia after esophagectomy. Exclusion criteria included previous stent placement for the same condition, tumor stricture within 2 cm of the upper esophageal sphincter, and tumor length of more than 10 cm.
All patients gave informed consent. The study protocol was reviewed and approved by the Medical Ethics Committees of all four participating centres and registered at the Dutch Trial Registration Site (NTR 3313).
stent placement
The Hanaro Flap stent is an SEMS constructed of nitinol alloy wire and fully covered with a silicone membrane. The diameter of the stent body is 20 mm, with flanges of 26 mm at each end ( Figure 1) . On the body of the stent, three rows of covered anti-migration flaps, with four flaps on each row, are attached. Each flap has a length of 2.5 mm and a width of 8.5 mm. Lassos at both stent ends allow repositioning after placement or stent retrieval. The stent is available in lengths of 8, 11, and 14 cm. A stent measuring at least 4 cm longer than the stricture was chosen in the current study to allow for overlap of at least 2 cm at the upper and lower border of the stricture. All procedures were performed with the patient under conscious sedation using midazolam or propofol. 
study end points
The primary end point of the study was recurrent dysphagia, with a particular focus on stent migration as the cause. Secondary end points included technical success of placement, functional outcome (dysphagia score), adverse events, and survival.
Recurrent dysphagia was defined as a dysphagia score of ≥2 after initial successful treatment of dysphagia. Dysphagia was scored according to Ogilvie (grade 0 = ability to eat a normal diet; grade 1 = ability to eat some solids; grade 2 = ability to swallow semisolids only; grade 3 = ability to swallow liquids only; grade 4 = complete dysphagia for liquids).
Technical success was defined as successful deployment and placement of the stent at the required location, verified by fluoroscopy and/or endoscopy. A severe adverse event was defined as an event with a (possible) association to the insertion procedure or to the stent and for which an (endoscopic) intervention or hospitalization was required. Adverse events could be treated conservatively with no need for hospitalization.
follow-up assessment
Patients were evaluated before stent placement, 14 days after stent placement, and monthly thereafter until death or stent removal. For patients still alive at the end of the study, the minimal duration of follow-up was 6 months and the maximum was 12 months. Evaluation included dysphagia score and symptoms of retrosternal pain and reflux. In cases of recurrent dysphagia, patients underwent endoscopy.
statistical analysis
Results were expressed as means (±SD) or medians (range), as appropriate. Dysphagiafree survival and overall survival were calculated according to the Kaplan-Meier method. Cox-regression analysis was performed to calculate hazard ratios (HR) and their corresponding 95% confidence intervals (CI) for predictors of migration and occurrence of adverse events. A P value of <0.05 was considered to be statistically significant. All analyses were performed using SPPS software version 20 (IBM Corp., Armonk, New York, USA). rEsults patient characteristics A total of 40 consecutive patients with malignant dysphagia due to esophageal cancer (n = 32), extrinsic malignant compression (n = 5; 4 lung cancers, 1 metastatic breast cancer), recurrent anastomotic cancer (n = 2), and gastric cardia cancer (n = 1) were included ( Table 1) . In four patients (10%), an esophageal-respiratory fistula was present at inclusion.
outcome and survival Placement of the Hanaro Flap stent was technically successful in all but one patient (98%). In this patient, the stent collapsed during repositioning using a rat tooth forceps and a second stent was placed inside the first stent. As there was no improvement of dysphagia, both stents were removed the next day and another stent was placed.
At 1 month after stent placement, all 39 patients with successful stent placement experienced improvement of the dysphagia score by at least 1 grade. The median dysphagia score improved, from 3 before stent placement to 1 at 1-month follow up.
A total of 30 patients were followed until death, 4 patients until stent removal, and 6 patients were still alive after a follow-up period of ≥6 months (range 181-365 days). The median survival after stent placement was 76 days (95%CI 59-93 days). The majority of patients (84%) died as a result of tumor progression. Three patients (10%) died of complications due to (aspiration) pneumonia, one patient (3%) from cardiac arrest, and one patient (3%) from tracheal compression due to tumor growth.
recurrent dysphagia
The median dysphagia-free time after stent placement was 220 days (95%CI 94-345 days). Nine patients (23%) experienced recurrent dysphagia because of stent migration (n = 6; 15%), tissue overgrowth (n = 2; 5%), or fracture of the stent (n = 1; 3%). Complete stent migration into the stomach was observed in one patient after 39 days, and this stent was removed during endoscopy followed by insertion of a new stent. In the other five patients with stent migration, the stent had migrated 2-6 cm distally after a median of 48 days (range 9-96 days). These stents were endoscopically repositioned. One patient returned twice thereafter with recurrent dysphagia due to partial stent migration, for which the stent was repositioned during repeat endoscopy. There were no statistically significant predictors of stent migration ( Table 2) . However, stent migration occurred in 3/6 patients (50%) undergoing ongoing treatment compared with only 3 of 33 patients without ongoing treatment (9%).
Tissue overgrowth was observed in two patients at 44 and 132 days after stent placement, respectively. A second overlapping stent was placed in one patient, and in the other patient the stent was removed and replaced. In one patient, the stent fractured at the level of the stent body 220 days after placement, and the lower part of the stent caused obstruction of the esophagus. A new stent was placed through the fractured stent.
adverse events A total of 16 severe adverse events occurred in 14 patients (36%) ( Table 3 ). The most common severe adverse event included hemorrhage in three patients. One patient had tumor growth into the left gastric artery resulting in three episodes of hematemesis, and two patients had one bleeding episode each. All patients were successfully treated with radiation therapy and/or blood transfusion. Severe nausea and/or vomiting requiring admission or feeding tube placement was reported in three patients. A new esophagealrespiratory fistula developed in two patients, after 45 and 166 days, respectively. One patient developed a fistula at the proximal stent end, and in this patient the stent was replaced by another stent type resulting in successful sealing of the fistula. The second patient presented with mediastinitis. An additional stent was placed at the level of contrast leakage. This patient died 2 days after the endoscopy due to septic complications. In one patient with a pre-existing fistula, partial migration of the stent resulted in an unsealed fistula. In this patient, a second Hanaro Flap stent was placed through the first stent, and thereafter a control contrast swallow showed no contrast leakage. Adverse events, particularly mild retrosternal pain (n = 11) and nausea and vomiting (n = 4), were seen in 19 of 39 patients (49%). All patients with mild retrosternal pain experienced this pain for a short period (<7 days), and it was successfully treated with a short course of low-dose analgesics. In the majority of patients, the pain resolved within 24 hours after stent placement.
Cox-regression analysis showed that prior radiation therapy and/or chemotherapy was not associated with an increased risk of severe adverse events (P = 0.13; HR 2.7, 95%CI 0.7-10.0) or adverse events (P = 0.23; OR 1.8, 95%CI 0.7-4.7).
discussion
In this prospective, multicenter, follow-up study, the Hanaro Flap stent provided relief of malignant dysphagia in the majority of patients. Although the recurrent dysphagia rate was relatively low, the stent migration rate was not reduced compared with other FCSEMS. This was somewhat surprising because this FCSEMS was specifically designed to reduce migration rates.
The main goal of palliative treatment in patients with inoperable malignant esophageal obstruction is to provide rapid and persistent relief of dysphagia. Although rapid relief of symptoms is achieved in almost all studies that have reported on results of SEMS placement, the occurrence of recurrent dysphagia has largely remained unchanged (i.e. at ~30%-40%). 2, 3 Compared with other studies, the 23% rate of recurrent dysphagia in the current study was relatively low.
It is known that stent migration is the main cause of recurrent dysphagia when FCSEMS are placed in the esophagus. 3 To prevent migration, several anti-migration features have been reported. However, results have been mixed: bilateral flared ends (5%-14% migration), 9, 10 anti-migration struts (36%), 11 or a double layered mesh (0-12%). 5, 10, 12 The migration rate of 15% in the current study is comparable to the rate for FCSEMS that have bilateral flared ends as their only anti-migration feature, suggesting that the flaps of the Hanaro Flap stent are of only limited value for the prevention of migration. However, it is important to note that migration was only partial in 5/6 patients in the current study, with a downward migration of a few centimeters seen during endoscopy. Nonetheless, all patients with migration had symptoms of recurrent dysphagia. In contrast, the majority of reported stent migrations with other SEMS were into the stomach. 5, 9, 11 In the current study, management of partial migration included endoscopic repositioning, which is relatively easy to perform and associated with lower costs than placement of a new stent. It is possible that increasing the number of flaps might result in prevention of partial migration.
Placement of the Hanaro Flap stent was associated with a high adverse event rate. Severe adverse events were reported in 36% of patients, which is in the upper range when compared with rates of 18%-36% with other FCSEMS. 3, 4, 9 An interesting finding was the occurrence of severe nausea and/or vomiting in three patients, as this is a not commonly reported adverse event after esophageal SEMS placement. Hirdes et al. recently reported frequent nausea and/or vomiting in a study in which single-dose brachytherapy was combined with biodegradable stent placement for dysphagia due to esophageal cancer. 13 The high axial force of the biodegradable stent was proposed to be a causative factor due to its negative effect on esophageal motility. However, this is unlikely to be the cause in the current study because recent in vitro testing showed that the Hanaro esophageal stent only has a moderate to low axial force.
14 Another explanation might be that severe nausea and/or vomiting was caused by impaired esophageal motility due to the malignant process. All three patients had undergone radiation therapy and two had also received chemotherapy before stent placement. Radiation therapy may induce esophageal damage in the form of necrosis and fibrosis, and concomitant chemotherapy could enhance this effect resulting in impaired esophageal motility.
A negative effect of radiation therapy and/or chemotherapy prior to stent placement has also been reported in previous studies on SEMS placement in the esophagus. It has been suggested that it increases the risk of (severe) adverse events, although this was not confirmed in all studies. 15 Although no association between prior radiation therapy and/ or chemotherapy and occurrence of (severe) adverse events was found, it should be taken into account, particularly when comparing these results with other studies, that a relatively high percentage of patients (64%) had undergone radiation therapy and/or chemotherapy in the current study.
Retrosternal pain was recorded in a significant number of patients (33%) in the current study and is also a commonly encountered adverse event after stent placement in other studies, with incidence rates ranging from 10% to 34%. 2, 4, 9, 11, 12 Nonetheless, a strict definition of retrosternal pain is not always used across studies; for example, in some studies only pain requiring admission or (high dose) opiates was reported, whereas in the current study, any retrosternal pain that required any form of pain medication was recorded as an adverse event; this might explain the high overall rate of retrosternal pain in 13 of 39 patients (33%). Furthermore, the thorough prospective follow-up schedule with specific attention to symptoms such as retrosternal pain and reflux may have also contributed to this high adverse event rate. Symptoms such as retrosternal pain are probably less frequently encountered in studies in which adverse events are collected retrospectively.
It is also possible that stent characteristics (e.g. anti-migration flaps) contributed to the occurrence of adverse events. Only a randomized study comparing the fully covered Hanaro stent with and without flaps will give a definitive answer as to whether the flaps induce adverse events. However, as the flaps are small in size (2.5 × 8.5 mm) and flexible, we think that they are unlikely to be the cause of adverse events.
The prospective follow-up schedule is one of the strengths of this study, particularly the first follow-up visit 2 weeks after stent placement, which is likely to be important with regard to the recording of procedure-related adverse events. The main limitations of the study are the lack of randomization and a control group. Moreover, there are differences in definitions of adverse events, follow-up schedule, and patient characteristics between reported studies. To overcome these limitations in future studies, we recently started an initiative to define end points for studies investigating stents in the gastrointestinal tract.
In conclusion, this study demonstrated that the Hanaro Flap stent is effective for the palliation of malignant dysphagia with a low recurrent dysphagia rate. However, despite the anti-migration features, stent migration was still a major cause of recurrent dysphagia. It is unclear whether the relatively high rate of adverse events was the result of the selected patient population and thorough follow-up or a result of stent characteristics.
